1. Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction
- Author
-
Wei Wang, MD, PhD, Liyan Zhang, PhD, Pavan K. Battiprolu, PhD, Arata Fukushima, MD, PhD, Khanh Nguyen, BS, Kenneth Milner, BS, Abhishek Gupta, PhD, Tariq Altamimi, PhD, Nikole Byrne, BS, Jun Mori, MD, PhD, Osama Abo Alrob, PhD, Cory Wagg, Natasha Fillmore, PhD, Shao-hua Wang, MD, PhD, Dongming M. Liu, BS, Angela Fu, BS, Jenny Yinglin Lu, BS, Mary Chaves, MS, Alykhan Motani, PhD, John R. Ussher, PhD, Jeff D. Reagan, PhD, Jason R.B. Dyck, PhD, and Gary D. Lopaschuk, PhD
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Summary: Alterations in cardiac energy metabolism after a myocardial infarction contribute to the severity of heart failure (HF). Although fatty acid oxidation can be impaired in HF, it is unclear if stimulating fatty acid oxidation is a desirable approach to treat HF. Both immediate and chronic malonyl coenzyme A decarboxylase inhibition, which decreases fatty acid oxidation, improved cardiac function through enhancing cardiac efficiency in a post–myocardial infarction rat that underwent permanent left anterior descending coronary artery ligation. The beneficial effects of MCD inhibition were attributed to a decrease in proton production due to an improved coupling between glycolysis and glucose oxidation. Key Words: fatty acid oxidation, heart failure, glucose oxidation, uncoupling of glycolysis
- Published
- 2019
- Full Text
- View/download PDF